News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Benzinga Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Scribe Therapeutics (SCTX) director Joshua Bleharski was granted 14,725 stock options with an exercise price of $15.00 per share, expiring on July 22, 2036. The options will vest in three equal annual installments on July 23 of 2027, 2028, and 2029, contingent on his …
Avoro Capital Advisors LLC, Avoro Ventures LLC, and Behzad Aghazadeh have reported a collective beneficial ownership of 16.37% in Scribe Therapeutics, Inc. (SCTX) common stock following the company's IPO. This stake, totaling 3,088,888 shares, arose from the conversion of Series B preferred stock, purchases …
Scribe Therapeutics CEO Benjamin L. Oakes received three option awards for the company's common stock. These include a fully vested grant of 12,969 options on March 13, 2026, and two grants on July 23, 2026: a time-based option for 264,784 shares vesting monthly over …
Scribe Therapeutics CFO David Parrot received significant equity awards, including time-vested and performance-based stock options totaling over 200,000 shares, both priced at $15.00. He also reported indirect open-market purchases of 2,666 common shares for family members at the same price. These transactions follow a …
Scribe Therapeutics (SCTX) ten percent owner Brett Staahl has filed an initial statement of beneficial ownership, reporting 524,336 shares of Common Stock held directly. Additionally, Staahl holds four stock option awards with various exercise prices and expiration dates ranging from 2030 to 2036, covering …
This article announces the filing of a Form 8K by E.W. Scripps Co Class A for August 7. It is a brief news item from Investing.com, providing basic information about the SEC filing. The content focuses solely on this financial disclosure, with no further …
E.W. Scripps reported a significant Q2 2026 loss of $12.68 per share, largely due to a $1.1 billion non-cash impairment charge related to its Scripps Networks business, and revenue fell short of forecasts. Despite the headline loss, the company's shares jumped 24% in after-hours …
CALGARY, AB, Aug. 5, 2026 /CNW/ -- Strathcona Resources Ltd. ("Strathcona" or the "Company") (TSX: SCR) today reported its second quarter 2026 financial and operating results. The Board of Directors also declared a quarterly dividend of $0.30 per common share.Strathcona Resources Ltd. Logo Q2 …
This article provides a brief mention of the free cash flow for Scribe Therapeutics Inc. (NASDAQ: SCTX) as found on TradingView. It appears to be a financial data point without further analysis or details within the snippet provided. The primary content available is navigational …
Kevin D. Littleton, President, Media of E.W. Scripps Co, has reported his initial beneficial ownership in the company. He directly holds 48,558 Class A Common Shares and also has restricted stock unit awards totaling 224,604 shares which are scheduled to vest between 2027 and …
Search by ticker symbol or company name and select a result to open its chart.